ID   LNCaP C4-2 neo
AC   CVCL_F0L3
SY   C4-2 neo
RX   PubMed=24740322;
CC   Population: Caucasian.
CC   Characteristics: Control cell line for LNCaP C4-2 AR-V7 (Cellosaurus=CVCL_F0L4) (PubMed=24740322).
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4782 ! LNCaP C4-2
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=24740322; DOI=10.1158/1078-0432.CCR-13-3296; PMCID=PMC4058390;
RA   Liu, Cheng-Fei
RA   Lou, Wei
RA   Zhu, Ye-Zi
RA   Nadiminty, Nagalakshmi
RA   Schwartz, Chad T.
RA   Evans, Christopher P.
RA   Gao, Allen C.
RT   "Niclosamide inhibits androgen receptor variants expression and
RT   overcomes enzalutamide resistance in castration-resistant prostate
RT   cancer.";
RL   Clin. Cancer Res. 20:3198-3210(2014).
//